{"data":{"id":"us/21-cfr-312.69","jurisdiction":"us","citation":"21 CFR 312.69","heading":"Handling of controlled substances.","body":"If the investigational drug is subject to the Controlled Substances Act, the investigator shall take adequate precautions, including storage of the investigational drug in a securely locked, substantially constructed cabinet, or other securely locked, substantially constructed enclosure, access to which is limited, to prevent theft or diversion of the substance into illegal channels of distribution.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER D—DRUGS FOR HUMAN USE","PART 312—INVESTIGATIONAL NEW DRUG APPLICATION","Subpart D—Responsibilities of Sponsors and Investigators"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"9b432e80191cc3637f621f6b4d41b76148239209f46e290c3427f26a34f79c17","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-312.68","next":"us/21-cfr-312.70"},"notice":"GroundRules: Original legal text. Not legal advice."}